The value of routine laboratory screening in the neonatal intensive care unit

J Neonatal Perinatal Med. 2020;13(2):247-251. doi: 10.3233/NPM-190239.

Abstract

Background: Healthcare spending is expected to grow faster than the economy over the next decade, and the cost of prematurity increases annually. The aim of this study was to investigate the frequency of intervention after routine laboratory testing in preterm infants.

Methods: This was a retrospective study of preterm infants (≤34 weeks) admitted to the NYU Langone Health NICU from June 2013 to December 2014. Data collected included demographics, results of laboratory tests, and resulting interventions. Intervention after a hemogram was defined as a blood transfusion. Intervention after a hepatic panel was defined as initiation or termination of ursodiol or change in dose of vitamin D. Subjects were stratified into 3 groups based on gestation (<28 weeks, 28-31 6/7 weeks, 32-34 weeks). Chi-square analysis was used to compare the frequency of intervention between the groups.

Results: A total of 135 subjects were included in the study. The frequency of intervention after a hemogram was 8.4% in infants <28 weeks, 4.6% in infants 28-31 6/7 weeks, and 0% in infants 32-34 weeks; this difference was found to be statistically significant (p = 0.02). The frequency of intervention after a hepatic panel was 4.2% in infants <28 weeks, 5.7% in infants 28-31 6/7 weeks, and 0% in infants 32-34 weeks, which was not found to be a statistically significant different.

Conclusion: No interventions were undertaken post-routine laboratory testing in any infant 32-34 weeks and routine testing in this population may be unnecessary. Further studies are needed to elucidate if routine testing affects neonatal outcomes.

Keywords: NICU; costs; hemograms; hepatic panel; laboratory screening.

MeSH terms

  • Alkaline Phosphatase / blood
  • Anemia / blood
  • Anemia / diagnosis*
  • Anemia / therapy
  • Bilirubin / blood
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Diseases, Metabolic / blood
  • Bone Diseases, Metabolic / diagnosis*
  • Bone Diseases, Metabolic / drug therapy
  • Cholagogues and Choleretics / therapeutic use*
  • Cholestasis / blood
  • Cholestasis / diagnosis*
  • Cholestasis / drug therapy
  • Cholestasis / etiology
  • Diagnostic Tests, Routine / economics
  • Diagnostic Tests, Routine / methods*
  • Erythrocyte Transfusion / statistics & numerical data
  • Female
  • Gestational Age
  • Health Care Costs
  • Health Expenditures
  • Hematocrit / economics
  • Hematocrit / methods
  • Humans
  • Infant, Extremely Premature
  • Infant, Newborn
  • Infant, Premature
  • Intensive Care Units, Neonatal
  • Liver Function Tests / economics
  • Liver Function Tests / methods
  • Male
  • Mass Screening / economics
  • Mass Screening / methods
  • Parenteral Nutrition, Total / adverse effects
  • Patient Selection
  • Retrospective Studies
  • Ursodeoxycholic Acid / therapeutic use
  • Vitamin D / administration & dosage

Substances

  • Bone Density Conservation Agents
  • Cholagogues and Choleretics
  • Vitamin D
  • Ursodeoxycholic Acid
  • Alkaline Phosphatase
  • Bilirubin